[go: up one dir, main page]

NO20063319L - Use of siramesin in the treatment of cancer - Google Patents

Use of siramesin in the treatment of cancer

Info

Publication number
NO20063319L
NO20063319L NO20063319A NO20063319A NO20063319L NO 20063319 L NO20063319 L NO 20063319L NO 20063319 A NO20063319 A NO 20063319A NO 20063319 A NO20063319 A NO 20063319A NO 20063319 L NO20063319 L NO 20063319L
Authority
NO
Norway
Prior art keywords
cancer
treatment
siramesin
administering
pharmaceutical compositions
Prior art date
Application number
NO20063319A
Other languages
Norwegian (no)
Inventor
Marcel Leist
Christian Thomsen
Marja Jaattela
Marie Stampe Andersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20063319L publication Critical patent/NO20063319L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfirmelse vedrører behandlingen av cancer. Spesielt tilveiebringer oppfirmelsen farmasøytiske sammensetninger omfattende siramesin for behandlingen av cancer. Oppfirmelsen tilveivbringer ytterligere en fremgangsmåte for behandling omfattende å administrere siramesin til en pasient som lider av cancer.The present invention relates to the treatment of cancer. In particular, the invention provides pharmaceutical compositions comprising siramesin for the treatment of cancer. The invention further provides a method of treatment comprising administering siramesin to a patient suffering from cancer.

NO20063319A 2003-12-19 2006-07-18 Use of siramesin in the treatment of cancer NO20063319L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53167003P 2003-12-19 2003-12-19
DKPA200301889 2003-12-19
PCT/DK2004/000885 WO2005058324A1 (en) 2003-12-19 2004-12-17 Use of siramesine in the treatment of cancer

Publications (1)

Publication Number Publication Date
NO20063319L true NO20063319L (en) 2006-07-18

Family

ID=34702153

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063319A NO20063319L (en) 2003-12-19 2006-07-18 Use of siramesin in the treatment of cancer

Country Status (8)

Country Link
EP (1) EP1715864A1 (en)
JP (1) JP2007514666A (en)
AU (1) AU2004298722A1 (en)
BR (1) BRPI0416019A (en)
CA (1) CA2550611A1 (en)
EA (1) EA011170B1 (en)
NO (1) NO20063319L (en)
WO (1) WO2005058324A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030453A1 (en) * 2000-08-15 2003-08-20 Lundbeck & Co As H PHARMACEUTICAL COMPOSITION WITH CONTENT OF 1 '[4- [1- (4-FLUOROPHENIL) -1H-INDOL-3-IL] -1-BUTIL] ESPIRO [ISOBENZOFURAN-1 (3H), 4'-PIPERIDINE]
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression

Also Published As

Publication number Publication date
CA2550611A1 (en) 2005-06-30
AU2004298722A1 (en) 2005-06-30
JP2007514666A (en) 2007-06-07
EP1715864A1 (en) 2006-11-02
BRPI0416019A (en) 2007-01-02
EA011170B1 (en) 2009-02-27
EA200600987A1 (en) 2006-10-27
WO2005058324A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
NO20044562L (en) Methods for treating bowel disease
NO20084652L (en) Deazapurins useful as inhibitors of januskinases
NO20050851L (en) Caspase Inhibitors and Uses thereof
MY169308A (en) Treatment of tnf? related disorders
CY1116215T1 (en) Combination therapy for the therapeutic treatment of Protein Deficiency Disorders
AU2004263179A8 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BR0214343A (en) 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1
WO2006086562A3 (en) Phenylazetidinone derivatives
CY1111470T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A
NO20052348L (en) Treatment of hemorrhagic shock
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
NO20061245L (en) Pharmaceutical compositions and processes comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphone
EA200601212A1 (en) PHOSPHODESTERASE INHIBITORS, OBTAINING AND THEIR THERAPEUTIC APPLICATION
NO20064325L (en) Heteroberlaminopyrazole derivatives useful for the treatment of diabetes
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200611695A (en) Pyrrolopyridine derivatives
NO20064078L (en) Substituted azetidine compositions, their preparation and use as drugs
NO20053042L (en) Use of spongosine (2-methoxyadenosine) for the treatment of pain, especially hyperalgesia.
NO20054371L (en) Somatostatin-dopamine chimeric analogs
EA200501821A1 (en) PHARMACEUTICAL COMBINATION, CONTAINING MODAFINIL AND OTHER DRUG PREPARATION
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
MX2007004955A (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally.
UA83821C2 (en) Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application